https://phrma.org/blogs/rss PhRMA Blog RSS Feed for Sitecore Send Repeatable Campaigns en-us 13523 https://phrma.org/blog/modernizing-340b-using-rapid-verification-the-case-for-a-rebate-model Elise Shutzer, April 20, 2026 As the 340B program has grown, the lack of safeguards has transformed it into an opaque system that often rewards revenue‑seeking over patient care. The Health Resources and Services Administration’s (HRSA) consideration of a rebate model pilot marks an important step toward addressing longstanding transparency and accountability challenges in the 340B program, issues that have only intensified as the program has rapidly grown and become more intertwined with other federal health care programs.   Mon, 20 Apr 2026 18:14:12 GMT 13504 https://phrma.org/blog/cms-undermines-medical-progress-with-mfn-price-controls Matthew Norawong, April 16, 2026 CMS is pushing a harmful MFN policy that threatens U.S. leadership in biopharmaceutical innovation and puts future treatments for patients at risk. Thu, 16 Apr 2026 04:00:00 GMT 13508 https://phrma.org/blog/icymi-measles-resurgence-could-cost-u-s-nearly-8-billion-over-five-years Andrew Powaleny, April 15, 2026 New research from researchers at the University of Florida, University of Maryland and Yale School of Public Health found that if MMR immunization rates continue to fall, even by just a percentage point, measles could reestablish itself as an endemic disease in the U.S. within years. Wed, 15 Apr 2026 20:37:33 GMT 13487 https://phrma.org/blog/trump-administration-s-efforts-to-have-other-countries-pay-their-fair-share-are-underway Hannah Loiacono, April 15, 2026 America’s leadership in pharmaceutical research and development powers global innovation. Decades of smart policies made the U.S. ecosystem the best in the world, providing American patients the greatest access to new medicines, supporting local economies and driving innovative breakthroughs. Wed, 15 Apr 2026 04:00:00 GMT 13480 https://phrma.org/blog/70-denied-how-insurance-denials-are-delaying-and-preventing-care-for-millions-of-americans Elise Shutzer, April 14, 2026 IQVIA, a health care consulting firm, released a new study showing that 70% of commercially insured patients were initially denied coverage for at least one newly prescribed brand medicine in 2024. That means seven out of ten patients were forced to delay needed treatments due to insurer policies that prioritize profit over patients. Tue, 14 Apr 2026 04:00:00 GMT 13434 https://phrma.org/blog/cms-mfn-proposals-won-t-help-seniors-despite-lofty-promises Brianna Allen, April 9, 2026 CMS is touting its Most Favored Nation (MFN) proposals as a way to make prescription medicines more affordable for seniors. But a closer look shows the policy is unlikely to lower patients’ out‑of‑pocket costs—and could even leave some seniors and people with disabilities paying more. Thu, 09 Apr 2026 04:00:00 GMT 13432 https://phrma.org/blog/voters-voice-concerns-on-government-price-controls Tom Wilbur, April 7, 2026 Across the country, patients and caregivers part of Voters for Cures are speaking out—and their message is clear: Most Favored Nation (MFN) policies put access to care at risk. While Americans strongly support lowering out-of-pocket costs, they believe MFN is not the solution. Instead of importing failed foreign pricing schemes, voters want policymakers to focus on the real drivers of health care costs—especially the abusive practices of insurance companies and middlemen. In fact, 83% of Americans agree policymakers should crack down on insurers and middlemen, not restrict access to medicines. Tue, 07 Apr 2026 04:00:00 GMT 13379 https://phrma.org/blog/virginia-should-be-cautious-about-importing-federal-price-setting-mechanisms Will May, April 1, 2026 PhRMA believes that discussions about the affordability of medicines are important and that these discussions should consider the entire drug supply chain. Transparency and accountability across the supply chain are important so that policymakers and patients can understand whether savings provided by manufacturers to insurers and pharmacy benefit managers (PBMs) are reaching patients at the pharmacy counter. However, recent price-setting legislation in Virginia could limit prescription options by failing to recognize the complexity of a pharmaceutical supply chain that functions nationally, not state by state, and by targeting only manufacturers.   Wed, 01 Apr 2026 13:02:12 GMT 13377 https://phrma.org/blog/policymakers-shouldn-t-double-down-on-the-ira-s-flaws-with-mfn Matthew Norawong, March 30, 2026 Policymakers are once again debating price controls, this time in the form of Most Favored Nation (MFN) drug pricing. Before repeating that mistake, they should look hard at how the last price-setting experiment—the Inflation Reduction Act (IRA)—is actually playing out.  Mon, 30 Mar 2026 04:00:00 GMT 13372 https://phrma.org/blog/argentina-sets-course-to-enable-innovation-by-rejecting-failed-patent-rules Anjam Aziz, March 26, 2026 After nearly 15 years, Argentina has rescinded a controversial set of patent rules that blocked groundbreaking treatments from reaching its patients, demonstrating a commitment to medical innovation that should be modeled by other countries. Thu, 26 Mar 2026 04:00:00 GMT 13371 https://phrma.org/blog/hospitals-drive-nearly-80-of-the-u-s-health-spending-gap Brianna Allen, March 25, 2026 The health care affordability debate in Washington is focused on drug prices while ignoring the largest drivers of health care spending. A new analysis from market research firm Magnolia shows the main factors driving health costs higher in the United States compared to other OECD countries are hospitals, clinics and outpatient care. Wed, 25 Mar 2026 14:28:51 GMT 13370 https://phrma.org/blog/16-years-later-how-bpcia-continues-to-expand-competition-and-lower-costs Jocelyn Ulrich, March 23, 2026 Sixteen years ago today, the United States enacted the Biologics Price Competition and Innovation Act (BPCIA), a landmark law that helped establish a strong, IP-driven and predictable regulatory system for biological innovation and competition. The groundbreaking legislation reshaped the biologics and biosimilars marketplace, expanding options for patients. Mon, 23 Mar 2026 04:00:00 GMT 13367 https://phrma.org/blog/key-context-is-often-missing-from-the-debate-over-the-patent-trial-and-appeal-board Andrew Powaleny, March 20, 2026 Voices arguing that inter partes review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB) are essential to speeding generic and biosimilar competition oversimplify how medicines come to market—risking weakening the innovation ecosystem patients rely on. Fri, 20 Mar 2026 04:00:00 GMT 13368 https://phrma.org/blog/congress-should-look-under-the-hood-of-340b-hospitals-don-t-want-them-to Molly Jenkins, March 19, 2026 What you should know: Big, tax-exempt hospitals are defending the 340B program with the same tired scare tactics, even as it operates more like a hospital markup scheme than a safety-net program. In 2023 alone, 340B medicine markups generated nearly $65 billion in profits for hospitals, clinics and their for-profit partners with no guardrails, transparency, or requirements that patients benefit.  Thu, 19 Mar 2026 19:31:02 GMT